A study by The National Institutes for Quantum Science and Technology in Japan found that a supplement with seven specific amino acids called Amino LP7 appeared to slow brain degeneration and dementia development in mice.
The drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer,” should not be used to prevent Covid-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said.
Single-patient study adds to debate over Gilead’s remdesivir for Covid-19
Antivirals, Azithromycin, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Studies, Doctors, Hydroxychloroquine, Medical Journals, Nature Communications, R&D, Remdesivir, Scientists, Survival Rates, World Health OrganizationA single-patient study conducted by British scientists found that Gilead’s remdesivir could be highly effective against Covid-19, raising questions about previous studies that found the antiviral drug had no impact on death rates from the disease.
As Death Toll Climbs, WHO Finds No Benefit with 4 Top Covid-19 Treatments
Antiretrovirals, Biopharma Companies, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Hospitalized COVID-19 Patients, Hydroxychloroquine, Interferon-beta-1a, Lopinavir, Mortality Rates, New England Journal of Medicine, R&D, Remdesivir, World Health OrganizationOnce touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.
The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
WHO study says remdesivir did not cut hospital stay or mortality in Covid-19 patients
Antivirals, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, Hospitalized COVID-19 Patients, Hydroxychloroquine, Immunomodulator Drugs, Monoclonal Antibodies, Mortality, R&D, Remdesivir, World Health OrganizationGilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
Severe Covid-19 riskier than heart attack for young adults; antibiotic shows no benefit
African-Americans, Antibiotics, Antimalarial, Azithromycin, Clinical Studies, Coronavirus Disease 2019 (COVID-19), Heart Attacks, Hispanics, Hospitalized COVID-19 Patients, Hydroxychloroquine, Lung Damage, Middle-Aged Adults, R&D, Surveys, Young AdultsA roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
The anti-malaria drug touted by U.S. President Donald Trump as a Covid-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
The World Health Organization is discontinuing the WHO’s trials of the malaria drug hydroxychloroquine and the combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.
A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.